More than ten biosimilars to Humira^® were launched in 2023, introducing price competitiveness for one of the most utilized drugs on the market....

Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...

This summer has seen a continuation of the long-awaited market entry of Humira^® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...

The market entry of biosimilars to Humira^® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...

As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.

Sharon Faust, PharmD, Vice President of Specialty Pharmacy for Lumicera shares a few key initiatives that will continue to create an impact for...

Navitus’ CEO, David Fields, shares his insights into the pharmacy benefits industry that will help plan sponsors achieve greater cost savings,...

Specialty medication development has grown rapidly, encompassing up to 80% of new FDA drug approvals in recent years. Read on to learn about the most...

Didn’t have time to attend our recent webinar on managing chronic conditions? Don’t worry – we’ve got you covered with a recap!

Provider-administered specialty drugs covered under the medical benefit can cost far more than their average wholesale price (AWP). As a result...

More than 75% of pharmaceutical manufacturers are choosing to limit the number of pharmacies that can dispense certain specialty medications.¹ Find...

Despite the pandemic, manufacturers are continuing to develop new drugs, especially specialty medications. Read on for the most important specialty...